SK1602001A3 - 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use - Google Patents

2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use Download PDF

Info

Publication number
SK1602001A3
SK1602001A3 SK160-2001A SK1602001A SK1602001A3 SK 1602001 A3 SK1602001 A3 SK 1602001A3 SK 1602001 A SK1602001 A SK 1602001A SK 1602001 A3 SK1602001 A3 SK 1602001A3
Authority
SK
Slovakia
Prior art keywords
alkyl
carbon atoms
group
aromatic
independently selected
Prior art date
Application number
SK160-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Fumitaka Ito
Hirohide Noguchi
Hiroshi Kondo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK1602001A3 publication Critical patent/SK1602001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK160-2001A 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use SK1602001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06
PCT/IB1999/001239 WO2000008013A2 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists

Publications (1)

Publication Number Publication Date
SK1602001A3 true SK1602001A3 (en) 2002-09-10

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
SK160-2001A SK1602001A3 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use

Country Status (44)

Country Link
US (1) US6172067B1 (id)
EP (1) EP1102762B1 (id)
JP (1) JP3367945B2 (id)
CN (1) CN1317968A (id)
AP (1) AP2001002063A0 (id)
AR (1) AR018686A1 (id)
AT (1) ATE227716T1 (id)
AU (1) AU749166B2 (id)
BG (1) BG105301A (id)
BR (1) BR9912778A (id)
CA (1) CA2339621C (id)
CZ (1) CZ2001397A3 (id)
DE (1) DE69903953T2 (id)
DK (1) DK1102762T3 (id)
EA (1) EA200100104A1 (id)
EE (1) EE200100075A (id)
ES (1) ES2185357T3 (id)
GE (1) GEP20033000B (id)
GT (1) GT199900125A (id)
HK (1) HK1040188A1 (id)
HN (1) HN1999000105A (id)
HR (1) HRP20010089B1 (id)
HU (1) HUP0103567A3 (id)
ID (1) ID27212A (id)
IL (1) IL141029A0 (id)
IS (1) IS5812A (id)
MA (1) MA26659A1 (id)
NO (1) NO20010603L (id)
NZ (1) NZ509299A (id)
OA (1) OA11590A (id)
PA (1) PA8477701A1 (id)
PE (1) PE20000868A1 (id)
PL (1) PL346211A1 (id)
PT (1) PT1102762E (id)
SI (1) SI1102762T1 (id)
SK (1) SK1602001A3 (id)
SV (1) SV1999000099A (id)
TN (1) TNSN99142A1 (id)
TR (1) TR200100403T2 (id)
TW (1) TW513424B (id)
UY (1) UY25659A1 (id)
WO (1) WO2000008013A2 (id)
YU (1) YU8201A (id)
ZA (1) ZA200100900B (id)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60023100T2 (de) 2000-01-05 2006-07-06 Pfizer Inc. Benzimidazol-Verbindungen zur Verwendung als ORL1-Rezeptor-Antagonisten
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US6969712B2 (en) 2000-11-15 2005-11-29 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SI1385518T1 (sl) 2001-04-18 2009-02-28 Euro Celtique Sa Benzimidazolonske spojine
BR0209128A (pt) * 2001-04-18 2005-11-01 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
CA2443938C (en) 2001-04-18 2010-06-22 R. Richard Goehring Spiroindene and spiroindane compounds as opioid ligands useful for treating pain
EP1598339B1 (en) * 2001-04-18 2009-06-24 Euro-Celtique S.A. 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
RU2299883C2 (ru) 2001-04-18 2007-05-27 Эро-Селтик, С.А. Соединения спиропиразола, содержащая их фармацевтическая композиция, способ модуляции опиоидного рецептора и способ лечения с применением таких соединений
JP2005502619A (ja) * 2001-07-02 2005-01-27 オメロス コーポレイション オピオイドレセプター様レセプター１アゴニストと交替でオピオイドレセプターアゴニストを投与することを含む、痛覚脱失を生成するための方法
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
US8067603B2 (en) 2003-09-25 2011-11-29 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20080021069A1 (en) * 2004-10-08 2008-01-24 Takeda Pharmaceutical Company Limited Receptor Function Regulating Agent
WO2006074991A1 (en) 2005-01-11 2006-07-20 Neurosearch A/S Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
US20090239880A1 (en) * 2006-07-03 2009-09-24 Ulrik Svane Sorensen Combinations of monoamine reuptake inhibitors and potassium channel activators
EP2280008B1 (en) * 2007-01-16 2013-05-29 Purdue Pharma L.P. Heterocyclic-substituted piperidines as orl-1 ligands
RU2488585C2 (ru) * 2007-08-31 2013-07-27 Пэдью Фарма Л.П. Замещенные пиперидиновые соединения хиноксалинового типа и их применение
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
DK2324013T6 (en) 2008-07-21 2014-12-15 Purdue Pharma Lp Substituted bridged piperidine compounds of quinoxalintype and uses thereof
RU2013109143A (ru) 2010-08-05 2014-09-10 Амджен Инк. Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы
US9169203B2 (en) 2012-01-06 2015-10-27 Novus International, Inc. Sulfoxide-based surfactants
RS57845B1 (sr) 2012-02-09 2018-12-31 Novus Int Inc Ciklični dimeri koji sadrže heteroatom
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
ES2703051T3 (es) 2012-07-12 2019-03-06 Novus Int Inc Composiciones de matriz y de capa para la protección de agentes bioactivos
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
EP2976077A4 (en) 2013-03-22 2016-11-30 Scripps Research Inst BENZIMIDAZOLES SUBSTITUTED AS MODULATORS OF A NOCICEPTIN RECEPTOR
RU2021101430A (ru) * 2014-03-20 2021-03-16 Капелла Терапьютикс, Инк. Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака
CN112707851A (zh) 2015-11-12 2021-04-27 诺华丝国际股份有限公司 作为溶剂的含硫化合物
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
CA2229202C (en) 1995-08-15 2008-05-20 Universite Libre De Bruxells Methods for identifying antagonist or agonist to human opioid receptor-like 1 "orl1"
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
AU2388697A (en) * 1996-04-19 1997-11-12 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP0813065A3 (en) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
EP0829481A1 (en) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
JP4366532B2 (ja) 1997-05-30 2009-11-18 萬有製薬株式会社 ２−オキソイミダゾール誘導体
WO1999003880A1 (en) 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
HK1040188A1 (zh) 2002-05-31
HRP20010089B1 (en) 2003-04-30
AU4385999A (en) 2000-02-28
ZA200100900B (en) 2002-08-28
ID27212A (id) 2001-03-08
HN1999000105A (es) 2000-11-11
HRP20010089A2 (en) 2002-02-28
IL141029A0 (en) 2002-02-10
AU749166B2 (en) 2002-06-20
EA200100104A1 (ru) 2001-08-27
EE200100075A (et) 2002-06-17
YU8201A (sh) 2003-07-07
NZ509299A (en) 2003-05-30
IS5812A (is) 2001-01-16
US6172067B1 (en) 2001-01-09
GEP20033000B (en) 2003-06-25
EP1102762A2 (en) 2001-05-30
NO20010603D0 (no) 2001-02-05
AR018686A1 (es) 2001-11-28
PL346211A1 (en) 2002-01-28
PT1102762E (pt) 2003-02-28
EP1102762B1 (en) 2002-11-13
MA26659A1 (fr) 2004-12-20
BG105301A (en) 2001-12-29
AP2001002063A0 (en) 2001-03-31
DE69903953D1 (de) 2002-12-19
SI1102762T1 (en) 2003-04-30
GT199900125A (es) 2001-01-27
WO2000008013A3 (en) 2000-03-23
PA8477701A1 (es) 2000-09-29
DK1102762T3 (da) 2002-12-16
JP3367945B2 (ja) 2003-01-20
HUP0103567A2 (hu) 2002-02-28
HUP0103567A3 (en) 2003-01-28
BR9912778A (pt) 2001-09-25
TW513424B (en) 2002-12-11
TNSN99142A1 (fr) 2005-11-10
NO20010603L (no) 2001-04-05
ATE227716T1 (de) 2002-11-15
CN1317968A (zh) 2001-10-17
JP2002522431A (ja) 2002-07-23
UY25659A1 (es) 2000-02-23
PE20000868A1 (es) 2000-08-31
WO2000008013A2 (en) 2000-02-17
CZ2001397A3 (cs) 2002-05-15
TR200100403T2 (tr) 2001-07-23
OA11590A (en) 2004-08-18
CA2339621C (en) 2005-04-05
CA2339621A1 (en) 2000-02-17
ES2185357T3 (es) 2003-04-16
DE69903953T2 (de) 2003-03-27
SV1999000099A (es) 2000-09-05

Similar Documents

Publication Publication Date Title
SK1602001A3 (en) 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use
US6423725B1 (en) 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
JP3276111B2 (ja) Ｏｒｌ１−レセプターアゴニストとしての２−ベンズイミダゾリルアミン化合物
US6294555B1 (en) 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
EP1499596B1 (en) Muscarinic antagonists
WO2000009506A1 (fr) Derives de 1h-imidazopyridine
CA2330092C (en) Benzimidazole compounds as orl1-receptor agonists
CA2444595A1 (en) Benzimidazolone derivatives
JP2007055940A (ja) ピラゾロピリミジン誘導体
JPWO2002040019A1 (ja) ベンズイミダゾール誘導体
JP2009511552A (ja) 置換１−アミノ−フタラジン誘導体、これらの調製およびこれらの治療的使用
WO2007111227A1 (ja) アシルアミノピペリジン化合物
IL161699A (en) Piperidine derivatives, process for their preparation, pharmaceutical compositions comprising them and uses thereof in the manufacture of medicaments
CA2582512A1 (en) Compounds, compositions containing them, preparations thereof and uses thereof ii
US20030109549A1 (en) 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists
EP2464646B1 (en) Process for the preparation of cathepsin s inhibitors
KR20110075017A (ko) Ｎｋ3 수용체 길항제로서 퀴나졸린 유도체
JPWO2006080519A1 (ja) ジアミン誘導体
WO2000031061A1 (fr) Derives de 2-oxo-imidazole
MXPA00007051A (en) 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists
MXPA01001331A (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
MXPA01000116A (en) Benzimidazole compounds as orl1-receptor agonists
MXPA99009765A (en) 1,3,8-triazaspiro[4.5]decanone compound as orl1-receptor agonist